Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 28, 2026

Arrowhead gains UK marketing authorisation for Redemplo

Arrowhead Pharmaceuticals has received marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Redemplo (plozasiran) as an adjunct to diet to reduce triglyceride levels in adults with familial chylomicronaemia syndrome (FCS).

The regulatory clearance was supported by results from the PALISADE study. Credit: PeopleImages / Shutterstock.com.